BIOLINERX LTD-SPONS ADR (BLRX)

US09071M2052 - ADR

0.3233  -0.22 (-40.7%)

After market: 0.325 +0 (+0.53%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOLINERX LTD-SPONS ADR

NASDAQ:BLRX (11/21/2024, 6:47:40 PM)

After market: 0.325 +0 (+0.53%)

0.3233

-0.22 (-40.7%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-52.57%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap25.85M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

BLRX Daily chart

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Company Info

BIOLINERX LTD-SPONS ADR

Modi'in Technology Park, 2 HaMa'ayan Street

Modiin 7177871

P: 97286429100

CEO: Philip A. Serlin

Employees: 79

Website: https://www.biolinerx.com/

BLRX News

ChartMill News Image4 hours ago - ChartmillThursday's session: top gainers and losers

What's going on in today's session

ChartMill News Image7 hours ago - ChartmillThursday's session: top gainers and losers

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

ChartMill News Image9 hours ago - ChartmillThursday's session: gap up and gap down stocks

Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

ChartMill News Image11 hours ago - ChartmillGet insights into the top gainers and losers of Thursday's pre-market session.

Get insights into the top gainers and losers of Thursday's pre-market session.

News Image13 hours ago - BioLineRx Ltd.BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

– BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as...

News Imagea day ago - BioLineRx Ltd.BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

BLRX Twits

Here you can normally see the latest stock twits on BLRX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example